Zoetis (NYSE:ZTS)

CAPS Rating: 4 out of 5

Results 1 - 11 of 11

Recs

0
Member Avatar line70day (< 20) Submitted: 12/2/2013 1:57:11 PM : Outperform Start Price: $31.28 ZTS Score: -4.91

Spin off from Pfizer animal health division Q income statement up 8% compared to same Q last yr. $1.1B. $706 M came from live segment. $ 397 from Animal division can boost funds. Acquired all of Advanced food technologies because of these investments profit dropped 19%

Recs

0
Member Avatar shaneatlas (72.22) Submitted: 10/9/2013 9:12:15 PM : Outperform Start Price: $31.57 ZTS Score: -14.74

exploding pet demographic

Recs

0
Member Avatar lanky522 (45.63) Submitted: 9/20/2013 3:46:55 PM : Outperform Start Price: $31.78 ZTS Score: -13.00

- Largest animal drug manufacturer.

- Recent split from parent PFE (companies normally operate more efficiently after they're split into logical operating pieces).

- Not exposed to the same patent -war and FDA approval fears that the rest of Large Pharma is.

Recs

0
Member Avatar 0500305474 (25.54) Submitted: 8/22/2013 12:00:11 AM : Outperform Start Price: $29.63 ZTS Score: -9.66

Spin off in great industry

Recs

0
Member Avatar HillCountryDungn (< 20) Submitted: 6/2/2013 11:15:18 PM : Outperform Start Price: $31.73 ZTS Score: -17.77

Sales growth is expanding fast, and spinoff from Pfizer should enhance economics.

Recs

0
Member Avatar ScubaSteveO (49.82) Submitted: 5/30/2013 7:43:49 AM : Outperform Start Price: $33.95 ZTS Score: -23.38

Zoetis has been the largest developer and manufacturer of veterinary vaccines and medicines and is the largest publicly traded animal health company; not a new company, but a recent spinoff from Pfizer. Zoetis is diversified in 120 different countries, with manufacturing facilities in 11 different countries and develops products specific to different areas of concerns geographically.

Revenue up 7% growth; both revenues in livestock and companion animals are up from a year ago, as well as 8% growth in earnings in the U.S. alone. First quarter up 4% in revenue and 26% in net income. One of their biggest products (Convenia), which is a one-time injection used to fight skin infections in cats and dogs was launched in China this March and is now available in 50 countries. They project an approx. $1 increase to EPS this year which includes the costs associated from its separation from Pfizer; it’s already up $1.89 per share from its initial price in Feb.

I believe Zoetis is prepared to stand on its own and is poised to succeed and have made it one of my own investments.

Recs

0
Member Avatar toegar2000 (49.35) Submitted: 3/2/2013 10:23:54 AM : Outperform Start Price: $34.42 ZTS Score: -35.53

Strong product line.

Recs

0
Member Avatar SoMch2Knw (79.74) Submitted: 2/19/2013 1:19:58 PM : Outperform Start Price: $33.39 ZTS Score: -31.59

Pfizer spin-off of animal care unit...

http://stockcharts.com/freecharts/gallery.html?ZTS

...should be an interesting development.

Recs

0
Member Avatar AFoolRushesIn (< 20) Submitted: 2/7/2013 2:53:30 PM : Outperform Start Price: $31.71 ZTS Score: -28.18

Pfizer seperating the animal health side of the business from the human side is a smart move.

Recs

0
Member Avatar chopchop0 (43.24) Submitted: 2/1/2013 3:50:45 PM : Outperform Start Price: $30.88 ZTS Score: -25.05

The first publicly-traded "pure play" animal health sciences company should do well over the long-term.

Recs

0
Member Avatar FutureMonkey (79.69) Submitted: 2/1/2013 3:30:10 PM : Outperform Start Price: $31.06 ZTS Score: -25.71

IPO of spin-off Animal Health unit of Pfizer,Inc. Nice open can't believe I forgot today was the day.

Results 1 - 11 of 11

Featured Broker Partners


Advertisement